Furthermore, the immunological landscape of breast cancer is complex and influenced by numerous factors beyond ANXA1 and MHC‐II expression, such as the presence of other immune checkpoints, the diversity of the tumor microenvironment, and individual patient variability. The gene discussed is ANXA1; the disease is neoplasm.